Amphion Innovations (A0J2VM) wurde von Richard Morgen aus der Taufe gehoben, einem Mitgründers der 20 Milliarden Euro schweren Biotech-Unternehmens Celgene......Näheres im Amphion Forum !! Wirklich sehr interessant !
|
|
|
Amphion Innovations (A0J2VM) wurde von Richard Morgen aus der Taufe gehoben, einem Mitgründers der 20 Milliarden Euro schweren Biotech-Unternehmens Celgene......Näheres im Amphion Forum !! Wirklich sehr interessant !
Celgene Corporation is a biopharmaceutical company with a market cap of over $12B engaged in the discovery, development and commercialization of novel therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic and proteomic targets. The Company has three major commercial-stage programs: Thalomid, Focalin (d-MPH) and cellular therapeutics. Thalomid is its lead product and was approved for sale in the United States in 1998. Thalomid is being evaluated in clinical trials for the treatment of solid tumor and hematological cancers, as well as serious inflammatory diseases. The Company also has a preclinical- and clinical-stage pipeline of new drug candidates and cell therapies, highlighted by seven classes of small molecule, orally administered therapeutic agents, including IMiDs (Immunomodulatory Drugs), SelCIDs (Selective Cytokine Inhibitory Drugs), SERMs (Selective Estrogen Receptor Modulators), benzopyrans, kinase inhibitors, tubulin inhibitors and ligase modulators.
Amphion and Celgene working together
Co-founder and lead initial investor in this broad based public biopharmaceutical company. Amphion partners have had active involvement on the board since inception. Provided funding, arranged outside funding and participated in the company's IPO. The Company's market capitalization is now well over $10 billion.
Ich hätte mal Fragen bzgl. der Quellensteuer, die die Schweiz auf die Dividende erhoben hat. Ist die Rückerstattung mit Kosten verbunden? Muss man den Tax-Voucher gesondert bei der Bank beantragen?
Auch für weitere Tipps bin ich dankbar!
Der Schweizer Pharmakonzern Novartis AG hat von der EU-Kommission die Zulassung für das Krebsmedikament Jakavi erhalten.
Weiterlesen auf www.transkript.de
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 60 | Cancer Drugs to watch: | geldschneider | 906866 A | 26.07.17 22:47 | |
1 | Genentech 48 % Gewinnsteigerung dank Krebs-"Drugs" | Mme.Eugenie | pacorubio | 14.03.08 11:01 | ||
40 | 2.864 | MophoSys - ExtraChancen | ecki | templer | 03.01.07 01:28 | |
81 | Depotwettbewerb USA 21 KW | Eskimato | Eskimato | 05.11.03 07:30 | ||
3 | Genentech | first-henri | first-henri | 09.07.03 23:24 |